Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact

Review Series

Targets for cancer therapy

Series edited by William G. Kaelin, Jr.

The series reviews a number of cellular processes that provide cancer drug targets, including angiogenesis, cell cycle and checkpoint control, growth factor signaling, and apoptosis. It also discusses target selection based on genomics and the specific case of the Abl inhibitor Gleevec.

Articles in series

Anticancer drug targets: approaching angiogenesis
Eli Keshet, Shmuel A. Ben-Sasson
Eli Keshet, Shmuel A. Ben-Sasson
Published December 1, 1999
Citation Information: J Clin Invest. 1999;104(11):1497-1501. https://doi.org/10.1172/JCI8849.
View: Text | PDF

Anticancer drug targets: approaching angiogenesis

  • Text
  • PDF
Abstract

Authors

Eli Keshet, Shmuel A. Ben-Sasson

×

Choosing anticancer drug targets in the postgenomic era
William G. Kaelin Jr.
William G. Kaelin Jr.
Published December 1, 1999
Citation Information: J Clin Invest. 1999;104(11):1503-1506. https://doi.org/10.1172/JCI8888.
View: Text | PDF

Choosing anticancer drug targets in the postgenomic era

  • Text
  • PDF
Abstract

Authors

William G. Kaelin Jr.

×

Anticancer drug targets: cell cycle and checkpoint control
Geoffrey I. Shapiro, J. Wade Harper
Geoffrey I. Shapiro, J. Wade Harper
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1645-1653. https://doi.org/10.1172/JCI9054.
View: Text | PDF

Anticancer drug targets: cell cycle and checkpoint control

  • Text
  • PDF
Abstract

Authors

Geoffrey I. Shapiro, J. Wade Harper

×

Apoptosis and cancer drug targeting
William R. Sellers, David E. Fisher
William R. Sellers, David E. Fisher
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1655-1661. https://doi.org/10.1172/JCI9053.
View: Text | PDF

Apoptosis and cancer drug targeting

  • Text
  • PDF
Abstract

Authors

William R. Sellers, David E. Fisher

×

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Brian J. Druker, Nicholas B. Lydon
Brian J. Druker, Nicholas B. Lydon
Published January 1, 2000
Citation Information: J Clin Invest. 2000;105(1):3-7. https://doi.org/10.1172/JCI9083.
View: Text | PDF

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

  • Text
  • PDF
Abstract

Authors

Brian J. Druker, Nicholas B. Lydon

×

Anticancer drug targets: growth factors and growth factor signaling
Jackson B. Gibbs
Jackson B. Gibbs
Published January 1, 2000
Citation Information: J Clin Invest. 2000;105(1):9-13. https://doi.org/10.1172/JCI9084.
View: Text | PDF

Anticancer drug targets: growth factors and growth factor signaling

  • Text
  • PDF
Abstract

Authors

Jackson B. Gibbs

×

Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts